RNAC vs ARQT vs REGN vs KYMR

For growth investors, Arcutis Biotherapeutics, Inc.

(ARQT) is the stronger pick with 91. 3% revenue growth year-over-year, versus -92. 8% for Cartesian Therapeutics, Inc. (RNAC). Regeneron Pharmaceuticals, Inc. (REGN) offers the better valuation at 17. 1x trailing P/E (15. 3x forward), making it the more compelling value choice. Analysts rate Cartesian Therapeutics, Inc. (RNAC) a "Buy" — based on 10 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On forward P/E, Regeneron Pharmaceuticals, Inc.

is actually cheaper at 15. 3x.

Over the past 5 years, Kymera Therapeutics, Inc.

(KYMR) delivered a total return of +92. 1%, compared to -91. 3% for Cartesian Therapeutics, Inc. (RNAC). Over 10 years, the gap is even starker: KYMR returned +154. 4% versus RNAC's -98. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Regeneron Pharmaceuticals, Inc.

(REGN) is the lower-risk stock at 0. 81β versus Cartesian Therapeutics, Inc. 's 2. 03β — meaning RNAC is approximately 152% more volatile than REGN relative to the S&P 500. On balance sheet safety, Arcutis Biotherapeutics, Inc. (ARQT) carries a lower debt/equity ratio of 3% versus 9% for Regeneron Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Arcutis Biotherapeutics, Inc.

(ARQT) is pulling ahead at 91. 3% versus -92. 8% for Cartesian Therapeutics, Inc. (RNAC). On earnings-per-share growth, the picture is similar: Arcutis Biotherapeutics, Inc. grew EPS 88. 8% year-over-year, compared to -52. 6% for Cartesian Therapeutics, Inc.. Over a 3-year CAGR, ARQT leads at 367. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Regeneron Pharmaceuticals, Inc.

(REGN) is the more profitable company, earning 31. 4% net margin versus -46. 6% for Cartesian Therapeutics, Inc. — meaning it keeps 31. 4% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: REGN leads at 24. 9% versus -31. 0% for RNAC. At the gross margin level — before operating expenses — RNAC leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Regeneron Pharmaceuticals, Inc.

(REGN) trades at 15. 3x forward P/E versus 77. 6x for Arcutis Biotherapeutics, Inc. — 62. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RNAC: 96. 1% to $16. 00.

In this comparison, REGN (0.

5% yield) pays a dividend. RNAC, ARQT, KYMR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Regeneron Pharmaceuticals, Inc.

(REGN) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 81)). Cartesian Therapeutics, Inc. (RNAC) carries a higher beta of 2. 03 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (REGN: +90. 0%, RNAC: -98. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: RNAC is a small-cap quality compounder stock; ARQT is a small-cap high-growth stock; REGN is a mid-cap deep-value stock; KYMR is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.